Catalyst Biosciences Inc. (CBIO): What Does Valuation Ratios Tell Us?


Catalyst Biosciences Inc. (NASDAQ:CBIO) saw an upside of 2.11% to $0.52 after adding $0.01 on Wednesday. The 5-day average trading volume is 632,513 shares of the company’s common stock. It has gained $0.5500 in the past week and touched a new high 2 times within the past 5 days. An average of 392,018 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 237,241.

CBIO’s 1-month performance is -6.85% or -$0.0275 on its low of $0.4801 reached on 12/16/22. The company’s shares have touched a 52-week low of $0.09 and high of $0.62, with the stock’s rally to the 52-week high happening on 08/25/22. YTD, CBIO has achieved 113.21% or -$0.3914 and has reached a new high 15 times. However, the current price is down -15.63% from the 52-week high price.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


Valuation Metrics

CBIO stock has a beta of 1.21. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 4.90 while the price-to-book (PB) in the most recent quarter is 0.55.

Catalyst Biosciences Inc.’s quick ratio for the period ended September 29 was 18.40, with the current ratio over the same period at 18.40. In terms of profitability, the gross margin trailing 12 months is -0.60%. The firm’s gross profit as reported stood at $42000.0 against revenue of $7.34 million.

Earnings Surprise

For the quarterly period ending September 29 this year, Net income shrunk -308.4% to -$4.88 million, while revenue of $51.63 million was 1157.99% off the previous quarter. Analysts expected CBIO to announce -$0.1 per share in earnings in its latest quarter, but it posted -$0.16, representing a -60.00% surprise. EBITDA for the quarter stood at more than -$5.13 million. CBIO stock balance sheet for the quarter ending September 29 shows that total liabilities totaled 1.64 million, with total debt at $0.38 million. Shareholders hold equity totaling $31.49 million.

Let’s look briefly at Catalyst Biosciences Inc. (CBIO) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 27 December was 57.94% to suggest the stock is trending Neutral, with historical volatility in this time period at 25.37%.

The stock’s 5-day moving average is $0.5052, reflecting a +5.36% or $0.0266 change from its current price. CBIO is currently trading -4.98% above its 20-day SMA, -72.05% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -10.70% and SMA200 by-12.90%.

Stochastic %K and %D was 45.18% and 34.06% and the average true range (ATR) pointed at 0.0262. The RSI (14) points at 47.56%, while the 14-day stochastic is at 60.80% with the period’s ATR at 0.0272. The stock’s 9-day MACD Oscillator is pointing at 0.0125 and 0.0101 on the 14-day charts.

Analyst Ratings

Analysts offering their rating for CBIO stock have a consensus rating for the stock as Hold. Currently, 0 brokerage advisors rate CBIO as a “sell,”, while 2 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 0 have offered a “buy” rating.

What is CBIO’s price target for the next 12 months?

Analysts have a consensus price target ranging from a low of $3.00 and a high of $3.00, with their median price target at $3.00. Looking at these predictions, the average price target given by analysts is for Catalyst Biosciences Inc. (CBIO) stock is $3.00.


Please enter your comment!
Please enter your name here